ArticlePlastic and reconstructive surgery. Global open2025
Comparison of Tranexamic Acid Administration Methods in Rhytidectomy: A Prospective, Randomized, Double-blind Study.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Trends in Facelift and Necklift Procedures.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tranexamic acid (TXA) is an antifibrinolytic agent with promising benefits in facial rejuvenation surgery. The best way to administer this medication for therapeutic value is currently unknown. This study compared outcomes for facelift patients given TXA intravenously versus locally in tumescent solution. Methods: Sixty rhytidectomy patients were randomized to receive 1 g of TXA intravenously or 150 mg of TXA in facial tumescent. Blood loss and surgeon-assigned bleeding rate were recorded intraoperatively for each side of the face. On postoperative day 7, patients assessed surgical satisfaction and bruising and swelling levels, and the surgeon graded ecchymosis and edema. Time to drain removal and complication incidence were also documented. Results: Mean blood loss was 25.86 mL for intravenous (IV) TXA patients versus 30.00 mL for local patients ( Conclusions: IV administration of TXA may have a slight advantage over local infiltration as it decreases days to drain removal and yields more precise outcomes for patient satisfaction and time to drain removal.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.